Invesaro

Stocks Health care QGEN

NYSE · Health care

Qiagen N.V. (QGEN)

Qiagen N.V. reported revenue of $2.1B in fiscal 2025, up 5.7% from a year earlier. Net income was $424.9M, a net margin of 20.3%. Operating cash flow minus capital spending left $453.3M of free cash flow in fiscal 2025. At December 31, 2025 it held $839M in cash against $1.7B of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 20, 2026.

Price
$44.18
-0.85% on the day · September 25, 2026
52-week range $32.53 to $57.82
Market cap
$9.1B
Revenue (FY2025)
$2.1B
+5.7% year on year
Net margin
20.3%

What Qiagen N.V. does

Qiagen N.V. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NYSE under the ticker QGEN.

Revenue and profit by year

Revenue
FY18: $1.5B $1.5B FY18FY19: $1.5B $1.5B FY19FY20: $1.9B $1.9B FY20FY21: $2.3B $2.3B FY21FY22: $2.1B $2.1B FY22FY23: $2B $2B FY23FY24: $2B $2B FY24FY25: $2.1B $2.1B FY25
Net income
FY18: $190.4M $190.4M FY18FY19: -$41.5M -$41.5M FY19FY20: $359.2M $359.2M FY20FY21: $512.6M $512.6M FY21FY22: $423.2M $423.2M FY22FY23: $341.3M $341.3M FY23FY24: $83.6M $83.6M FY24FY25: $424.9M $424.9M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$2.1B$465.9M$424.9M$1.94$453.3M
2024$2B$97.7M$83.6M$0.37$506.4M
2023$2B$409.9M$341.3M$1.48$309.7M
2022$2.1B$531.5M$423.2M$1.84$586M
2021$2.3B$630.1M$512.6M$2.21$449.1M
2020$1.9B$386.4M$359.2M$1.53$325M

Latest SEC filings

What Qiagen N.V. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 9, 2026
    Foreign issuer update 6-K
  2. August 7, 2026
    Foreign issuer update 6-K
  3. August 7, 2026
    Foreign issuer update 6-K
  4. August 7, 2026
    Foreign issuer update 6-K
  5. June 5, 2026
    Passive stake changed SCHEDULE 13G/A
  6. June 1, 2026
    Conflict minerals disclosure SD
  7. May 8, 2026
    Foreign issuer update 6-K
  8. May 8, 2026
    Foreign issuer update 6-K
  9. May 1, 2026
    Foreign issuer update 6-K
  10. March 20, 2026
    Form IRANNOTICE filing IRANNOTICE

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 15, 2025. Insider transactions on SEC

All filings on SEC EDGAR

Questions about QGEN

What does Qiagen N.V. do?

Qiagen N.V. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NYSE under the ticker QGEN.

Is Qiagen N.V. profitable?

Yes. In fiscal 2025 it reported net income of $424.9M on revenue of $2.1B, a net margin of 20.3%.

How much revenue does Qiagen N.V. make?

In fiscal 2025 Qiagen N.V. reported revenue of $2.1B. That is 5.7% more than a year earlier.

When did Qiagen N.V. last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 20, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 9, 2026.

Similar companies

AMGN
Amgen Inc
GILD
Gilead Sciences, Inc.
BIIB
Biogen Inc.
BNTX
BioNTech SE
NBIX
Neurocrine Biosciences Inc
EXEL
Exelixis, Inc.

Follow QGEN

Get an email when Qiagen N.V. files with the SEC: results, executive changes, material agreements and annual reports.

Follow QGEN: get an email when it files

Where the numbers come from

Financial figures are the values Qiagen N.V. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.